ResMed: Digital Health Drives Q2 Growth @themotleyfool #stocks $RMD

ResMed: Digital Health Drives Q2 Growth @themotleyfool #stocks $RMD

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.

ResMed Reports 10% Revenue Growth, Sees Wearables and GLP-1s Driving Future Demand

CEO sees “once-in-a-generation” opportunities in sleep-tracking wearables and GLP-1 therapies to drive patient flow. Summary: ResMed reported 10% revenue growth for the quarter ending Dec 31, 2024, reaching $1.3 billion, driven by strong demand for sleep devices, masks, and residential care software. CEO Mick Farrell highlighted “once-in-a-generation” opportunities presented by the rise of sleep-tracking wearables and GLP-1 therapies, which he b…

ResMed shares rise on strong Q2 result

ResMed Inc (ASX: RMD) shares are rising on Friday morning. At the time of writing, the sleep disorder treatment company's shares are up 0.5% to $40.70. This follows the release of the company's second quarter update before the market open. ResMed shares higher on Q2 update For the three months ended 31 December, ResMed reported a 10% increase in revenue to US$1.3 billion. This was ahead of the US$1,265 million that Goldman Sachs was forecasting …